Research into CRISPR gene editing technology continues to expand the amount of potential applications, while shrinking the actual size of proteins…
McAlinden Research PartnersSeptember 8, 2021
Promising developments in new gene editing trials continue to drive investor interest in the growing biotech sector. Potential advancements include the…
McAlinden Research PartnersJuly 22, 2021
Encouraging results from recent clinical trials testing the efficacy of using psychedelics like arketamine, LSD, and psilocybin to treat mental…
McAlinden Research PartnersMay 24, 2021
President Trump's bout of COVID-19 launched countless headlines regarding the some of the leading experimental treatments he'd be receiving - therapeutics…
McAlinden Research PartnersOctober 13, 2020
Emerging market healthcare stocks were on fire earlier in the year. While they have taken a breather recently, MRP believes…
McAlinden Research PartnersSeptember 17, 2020
New developments in advanced methods of CRISPR, particularly in base and prime editing, continue to propel the popularity of the…
McAlinden Research PartnersSeptember 1, 2020
Treatments utilizing Clustered Regularly Interspace Short Palindromic Repeats (CRISPR), continue to rack up clinical success. The latest research on blood…
McAlinden Research PartnersJune 16, 2020
Though many sectors have been whacked by the Coronavirus-related hurdles in 2020, research and development of the gene editing technology…
McAlinden Research PartnersMay 13, 2020
All sizes of pharmaceutical firms from giants like Johnson & Johnson to young guns like Moderna, yet to bring their…
McAlinden Research PartnersApril 1, 2020
